Skip to main content
Livermore
Livermore
ZHEN

Rocket Pharmaceuticals, Inc.

RCKT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001281895

In the last 90 days, Rocket Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 7 sales; 180 institutions reported holding it in 13F filings for Q2 2026, worth $340.9M in total; Maverick Capital is the only superinvestor holding it.

Superinvestors holding RCKT, Q2 2026

1 superinvestor reports holding Rocket Pharmaceuticals, Inc. on Form 13F, worth $13.4M in total. Weight is Rocket Pharmaceuticals, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.

See all superinvestors
Superinvestors holding RCKT in Q2 2026
Superinvestor% of portfolioSharesValuevs. previous quarter
Maverick CapitalLee Ainslie0.1%3,923,963$13.4MAdded+10.0%

Moves by quarter

Superinvestors that opened, added to, trimmed or sold out of RCKT each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.

  1. Q2 2026

    1 superinvestor holding at quarter end

    Added
    Maverick Capital (+10.0%)

  2. Q1 2026

    1 superinvestor holding at quarter end

    Added
    Maverick Capital (+42.0%)

  3. Q4 2025

    1 superinvestor holding at quarter end

    Reduced
    Maverick Capital (−70.3%)

  4. Q3 2025

    1 superinvestor holding at quarter end

    Added
    Maverick Capital (+1.2%)

  5. Q2 2025

    1 superinvestor holding at quarter end

    Added
    Maverick Capital (+60.9%)

  6. Q1 2025

    1 superinvestor holding at quarter end

    Added
    Maverick Capital (0.0%)

  7. Q4 2024

    1 superinvestor holding at quarter end

    Added
    Maverick Capital (+26.2%)

  8. Q3 2024

    1 superinvestor holding at quarter end

    Added
    Maverick Capital (+4.8%)

  9. Q2 2024

    1 superinvestor holding at quarter end

    Added
    Maverick Capital (+1.0%)

  10. Q1 2024

    1 superinvestor holding at quarter end

    Reduced
    Maverick Capital (−3.6%)

  11. Q4 2023

    1 superinvestor holding at quarter end

    Reduced
    Maverick Capital (−28.3%)

  12. Q3 2023

    1 superinvestor holding at quarter end

    Added
    Maverick Capital (+28.5%)

  13. Q2 2023

    1 superinvestor holding at quarter end

    Reduced
    Maverick Capital (−0.6%)

  14. Q1 2023

    1 superinvestor holding at quarter end

    Added
    Maverick Capital (+29.8%)

  15. Q4 2022

    1 superinvestor holding at quarter end

    Added
    Maverick Capital (+34.1%)

  16. Q2 2022

    1 superinvestor holding at quarter end

    Added
    Maverick Capital (+18.7%)

  17. Q1 2022

    1 superinvestor holding at quarter end

    Added
    Maverick Capital (+12.6%)

  18. Q4 2021

    1 superinvestor holding at quarter end

    Added
    Maverick Capital (+14.1%)

  19. Q3 2021

    1 superinvestor holding at quarter end

    Added
    Maverick Capital (+854.7%)

  20. Q2 2021

    1 superinvestor holding at quarter end

    New
    Maverick Capital